160 related articles for article (PubMed ID: 34304979)
21. Efficient Single-Strand Break Repair Requires Binding to Both Poly(ADP-Ribose) and DNA by the Central BRCT Domain of XRCC1.
Polo LM; Xu Y; Hornyak P; Garces F; Zeng Z; Hailstone R; Matthews SJ; Caldecott KW; Oliver AW; Pearl LH
Cell Rep; 2019 Jan; 26(3):573-581.e5. PubMed ID: 30650352
[TBL] [Abstract][Full Text] [Related]
22. Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020).
Velagapudi UK; Patel BA; Shao X; Pathak SK; Ferraris DV; Talele TT
Expert Opin Ther Pat; 2021 Jul; 31(7):609-623. PubMed ID: 33554679
[TBL] [Abstract][Full Text] [Related]
23. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
24. A quantitative assay reveals ligand specificity of the DNA scaffold repair protein XRCC1 and efficient disassembly of complexes of XRCC1 and the poly(ADP-ribose) polymerase 1 by poly(ADP-ribose) glycohydrolase.
Kim IK; Stegeman RA; Brosey CA; Ellenberger T
J Biol Chem; 2015 Feb; 290(6):3775-83. PubMed ID: 25477519
[TBL] [Abstract][Full Text] [Related]
25. In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Salmas RE; Unlu A; Yurtsever M; Noskov SY; Durdagi S
J Enzyme Inhib Med Chem; 2016; 31(1):112-20. PubMed ID: 26083304
[TBL] [Abstract][Full Text] [Related]
26. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
27. Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
Thomas C; Ji Y; Lodhi N; Kotova E; Pinnola AD; Golovine K; Makhov P; Pechenkina K; Kolenko V; Tulin AV
EBioMedicine; 2016 Nov; 13():90-98. PubMed ID: 27727003
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
29. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Cao R
J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
[TBL] [Abstract][Full Text] [Related]
30. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Karlberg T; Hammarström M; Schütz P; Svensson L; Schüler H
Biochemistry; 2010 Feb; 49(6):1056-8. PubMed ID: 20092359
[TBL] [Abstract][Full Text] [Related]
32. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
33. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
34. Targeted therapy for brain tumours: role of PARP inhibitors.
Leonetti C; Biroccio A; Graziani G; Tentori L
Curr Cancer Drug Targets; 2012 Mar; 12(3):218-36. PubMed ID: 22268386
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) polymerase inhibition: past, present and future.
Curtin NJ; Szabo C
Nat Rev Drug Discov; 2020 Oct; 19(10):711-736. PubMed ID: 32884152
[TBL] [Abstract][Full Text] [Related]
36. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
37. NADP
Bian C; Zhang C; Luo T; Vyas A; Chen SH; Liu C; Kassab MA; Yang Y; Kong M; Yu X
Nat Commun; 2019 Feb; 10(1):693. PubMed ID: 30741937
[TBL] [Abstract][Full Text] [Related]
38. Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
Mgoboza C; Okunlola FO; Akawa OB; Aljoundi A; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):495-504. PubMed ID: 35588345
[TBL] [Abstract][Full Text] [Related]
39. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
40. Specificity of protein interactions mediated by BRCT domains of the XRCC1 DNA repair protein.
Beernink PT; Hwang M; Ramirez M; Murphy MB; Doyle SA; Thelen MP
J Biol Chem; 2005 Aug; 280(34):30206-13. PubMed ID: 15987676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]